RATIFY: Prognostic impact of FLT3 tyrosine kinase domain (TKD) and NPM1 mutation status in patients with newly diagnosed acute myeloid leukemia (AML) treated with midostaurin or placebo plus standard chemotherapy (Alliance)
- Citation:
- Blood vol 132 (Suppl 1) 2668
- Meeting Instance:
- ASH 2018
- Year:
- 2018
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U10CA180820, U10CA180791, U10CA180888, U10CA180863, (CCSRI) #704970, U24CA196171
- Corr. Author:
- Authors:
- Maria Teresa Voso Richard A. Larson Thomas W Prior Guido Marcucci Dan Jones Jürgen Krauter Michael Heuser Serena Lavorgna Josep Noedeu Kristine Laumann Susan M. Geyer Rebecca B. Klisovic Andrew Wei Jorge Sierra Miguel A. Sanz Joseph M. Brandwein T. M. M de Witte Joop H. Jansen Dietger Niederwieser Frederick R. Appelbaum Bruno C. Medeiros Martin S. Tallman Richard F. Schlenk Arnold Ganser Hubert Serve Gerhard Ehninger Sergio Amadori Yuan Cheng Insa Gathmann Eva Tiecke Christian Thiede Konstanze Döhner Hartmut Döhner Richard M. Stone Clara D. Bloomfield Francesco Lo-Coco
- Networks:
- CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-OH007, LAPS-WI013
- Study
- CALGB-10603
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: